We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01687244
First Posted: September 18, 2012
Last Update Posted: July 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
FKD Therapies Oy
  Purpose
This Phase 2 study is designed to assess the efficacy and safety of INSTILADRIN (rAd-IFN with Syn3) when given intravesically to patients with high grade non-muscle invasive bladder cancer who are refractory to or have relapsed from BCG therapy. The pharmacodynamics of INSTILADRIN will also be studied by measuring the interferon (IFNα2b) levels excreted in the urine. rAd-IFN is a non-replicating recombinant adenovirus type 5 (Ad5)-vector encoding the interferon alpha-2b (IFNα2b) gene. Syn 3 is clinical surfactant excipient which enhances the ability of the adenoviral vector to transfect cells in the bladder wall.

Condition Intervention Phase
Superficial Bladder Cancer Drug: INSTILADRIN Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Masking Description:
The participant did not know if they received a high or low dose.
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Superficial Bladder Cancer

Resource links provided by NLM:


Further study details as provided by FKD Therapies Oy:

Primary Outcome Measures:
  • Incidence of High Grade-Recurrence Free Survival at 360 Days [ Time Frame: 360 Days ]
    Following the initial treatment, patients were clinically evaluated and re-treated at the Days 90, 180, and 270 time points, as outlined below. The decision to repeat treatment was determined by the clinical response observed following the previous treatment(s). Patients were assessed for High-Grade disease recurrence by cytology, cystoscopy and, if clinically indicated, biopsies were performed to obtain accurate staging. If no evidence of recurrence of High-Grade disease was detected, then a further dose of rAd-IFN/Syn3 was administered as maintenance therapy. Patients who had recurrence of High-Grade disease were withdrawn from treatment but were followed for survival and time to cystectomy. At 360 Days, a final efficacy evaluation was performed for patients receiving 4 doses of drug. This included cystoscopy, cytology, and biopsy.


Secondary Outcome Measures:
  • Safety of rAd-IFN/Syn3 [ Time Frame: 360 Days ]
    Treatment Emergent Adverse Events (AEs) for patients receiving study drug were described by NCI-CTCAE V4.03 terminology according to System Organ Class.

  • Incidence of High Grade Recurrence-Free Survival at 3 Months (90 Days). [ Time Frame: 90 Days ]
    All patients were evaluated 3 Months (90 Days) after the start of treatment for recurrence of high grade disease by cytology, cystoscopy, and biopsy if clinically indicated. Patients that we free of High-Grade disease recurrence received another dose. Data are presented as the number and percent of patients with High-Grade disease recurrence.

  • Incidence of High Grade-Recurrence-Free Survival at 6 Months (180 Days). [ Time Frame: 180 Days ]
    All patients were evaluated 6 Months (180 Days) after the start of treatment for recurrence of high grade disease by cytology, cystoscopy, and biopsy if clinically indicated. Patients that we free of High-Grade disease recurrence received another dose. Data are presented as the number and percent of patients with High-Grade disease recurrence.

  • Incidence of High Grade-Recurrence-Free Survival at 9 Months (270 Days). [ Time Frame: 270 Days ]
    All patients were evaluated 9 Months (270 Days) after the start of treatment for recurrence of high grade disease by cytology, cystoscopy, and biopsy if clinically indicated. Patients that we free of High-Grade disease recurrence received a final dose. Data are presented as the number and percent of patients with High-Grade disease recurrence.

  • Incidence of Cystectomy in All Patients [ Time Frame: 360 Days ]
    This secondary objective measures the incidence of cystectomy at 360 Days for the Efficacy Analysis Set.

  • Overall Survival in All Patients. [ Time Frame: 360 Days ]
    Overall survival was defined as the number who survived from the first dose of rAd-IFN/Syn3 to the end of the primary assessment (360 Days) or Withdrawal.

  • Number of Patients With Elevated Levels of Viral Vector in Blood [ Time Frame: 103 Days ]
    The level of viral vector as measured by qPCR in blood was determined in all patients on the initial day of dosing Day 1 (pre-dose) and at Day 2, Day 4, Day 12, and for patients that were free of High-Grade disease recurrence and received a second dose at Day 91 (pre-dose), Day 92, Day 94, and Day 103.

  • Number of Patients With Elevated Levels of Viral Vector in Urine [ Time Frame: 103 Days ]
    The level of viral vector as measured by qPCR in urine was determined in all patients on the initial day of dosing Day 1 (pre-dose) and at Day 2, Day 4, Day 12, and for patients that were free of High-Grade disease recurrence and received a second dose at Day 91 (pre-dose), Day 92, Day 94, and Day 103.

  • Number of Patients With Elevated IFN alpha2b Protein Levels in Serum [ Time Frame: 360 Days ]
    The levels of serum IFN alpha2b protein as measured by ELISA were determined in all patients on the initial day of dosing (Pre-Dose Day 1), at Day 2, Day 4, Day 12, and for patients that were free of High-Grade disease recurrence and received subsequent doses at Day 91 (pre-dose), Day 92, Day 94, Day 103, Day 180 (pre-dose), Day 270 (pre-dose), and Day 360 or Withdrawal.

  • Number of Patients With Elevated IFN alpha2b Protein Levels in Urine [ Time Frame: 103 Days ]
    The levels of urine IFN alpha2b protein as measured by ELISA were measured in all patients on the initial day of dosing Day 1 (pre-dose) and at Day 2, Day 4, Day 12, and for patients that did not have recurrence of HGD and received a second dose at Day 91 (pre-dose), Day 92, Day 94, and Day 103.

  • Number of Patients With Elevated Levels of Anti-IFN alpha2b Antibodies in Serum [ Time Frame: 360 Days ]
    The levels of serum anti-IFN alpha2b antibodies as measured by ELISA were determined in all patients on the initial day of dosing (Pre-Dose Day 1), at Day 12, and for patients that were free of High-Grade disease recurrence and received subsequent doses at Day 180 (pre-dose), Day 270 (pre-dose), and Day 360 or Withdrawal.

  • Number of Patients With Elevated Levels of Anti-Adenovirus Type 5 Antibodies in Serum. [ Time Frame: 360 Days ]
    The levels of serum anti-adenovirus type 5 antibodies as measured by ELISA were determined in all patients on the initial day of dosing (Pre-Dose Day 1), at Day 12, and for patients that were free of High-Grade disease recurrence and received subsequent subsequent doses at Day 180 (pre-dose), Day 270 (pre-dose), and Day 360 or Withdrawal.


Enrollment: 40
Study Start Date: September 2012
Study Completion Date: January 2016
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: rAd-IFN Dose 1x10^11vps/ml
Subjects will be randomly assigned to one of two INSTILADRIN arms.
Drug: INSTILADRIN
The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.
Other Name: rAd-IFN/Syn3
Experimental: rAd-IFN dose 3x10^11 vps/ml
Subjects will be randomly assigned to one of two INSTILADRIN arms.
Drug: INSTILADRIN
The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.
Other Name: rAd-IFN/Syn3

Detailed Description:

Criteria for Evaluation:

Efficacy: A Response is defined as no evidence of recurrence of a high grade tumor by cystoscopy, cytology or if clinically indicated, biopsy.

Safety: The safety and tolerability of INSTILADRIN will be evaluated based on adverse event reports, vital signs, ECGs, clinical laboratory values and results of physical examination.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Aged 18 years or older at the time of consent
  2. Able to give informed consent
  3. Subjects with high grade BCG-refractory or relapsed NMIBC including

    • High grade non-invasive papillary carcinomas (Ta) and subjects with high grade tumors that invade sub-epithelial connective tissue (T1) or
    • Carcinoma in situ (CIS) only or
    • CIS and Ta or T1 tumors Refractory is defined as failure to achieve a disease-free state at six months after adequate induction of BCG therapy with either maintenance or re-induction at 3 months. Adequate induction is defined as a minimum of 5 out of 6 induction doses and adequate maintenance is defined as a minimum of 2 out of 3 doses of treatment.

    Relapse is defined as recurrence within 1 year after a complete response to BCG treatment

  4. Complete resection of visible papillary lesions or CIS by TURBT or endoscopic resection between 14 and 60 days prior to beginning study treatment
  5. Available for the whole duration of the study
  6. Life expectancy >2 years, in the opinion of the investigator
  7. ECOG status 2 or less
  8. Absence of upper tract urothelial carcinoma
  9. Female subjects of childbearing potential must use maximally effective birth control during the period of therapy, must be willing to use contraception for 1 month following the last study drug infusion and must have a negative urine or serum pregnancy test upon entry into this study. Otherwise, female subjects must be postmenopausal (no menstrual period for a minimum of 12 months) or surgically sterile.
  10. Male subjects must be surgically sterile or willing to use a double barrier contraception method upon enrollment, during the course of the study, and for 1 month following the last study drug infusion.
  11. Adequate laboratory values.

    • Hemoglobin ≥10 g/dL.
    • WBC ≥4000/μL.
    • ANC ≥2000/μL.
    • Platelet count ≥100,000/μL.
    • INR within institutional normal limits.
    • aPTT within institutional normal limits.
    • AST ≤1.5 x ULN.
    • ALT ≤1.5 x ULN.
    • Total bilirubin within institutional normal limits.
    • Creatinine ≤1.5 x ULN.

Exclusion Criteria:

  1. Current or previous evidence of muscle invasive or metastatic disease
  2. Current systemic therapy for bladder cancer
  3. Current or prior pelvic external beam radiotherapy
  4. Prior treatment with adenovirus-based drugs
  5. Suspected hypersensitivity to interferon alpha
  6. Existing urinary tract infection or bacterial cystitis
  7. Clinically significant and unexplained elevated liver or renal function tests
  8. Women who are pregnant or lactating
  9. Severe cardiovascular disease
  10. History of malignancy of other organ system within past 5 years (except treated basal cell carcinoma or squamous cell carcinoma of the skin)
  11. Subjects who cannot hold instillation for 1 hour
  12. Subjects who cannot tolerate intravesical dosing or intravesical surgical manipulation
  13. Intravesical therapy within 6 weeks of enrollment
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01687244


Sponsors and Collaborators
FKD Therapies Oy
Investigators
Study Chair: Colin Dinney, MD M.D. Anderson Cancer Center
  More Information

Responsible Party: FKD Therapies Oy
ClinicalTrials.gov Identifier: NCT01687244     History of Changes
Other Study ID Numbers: rAd-IFN-CS-002
First Submitted: September 6, 2012
First Posted: September 18, 2012
Results First Submitted: January 9, 2017
Results First Posted: May 30, 2017
Last Update Posted: July 24, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: A manuscript will be published on the results of the study

Keywords provided by FKD Therapies Oy:
BCG Refractory or Relapsed Superficial Bladder Cancer
rAd-IFN
Syn3
Intravesical
transitional cell carcinoma of the bladder
superficial non-muscle invasive tumor
Interferon alpha2b
INSTILADRIN

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases